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INTRODUCTION 
   Acute Renal Failure (ARF) has traditionally been defined as the abrupt loss of kidney function 
that results in the retention of urea and other nitrogenous waste products and in the dysregulation 
of extra cellular volume and electrolytes. (1)The loss of kidney function is most easily detected by 
measurement of the serum creatinine which is used to estimate the glomerular filtration rate 
(GFR). 
  ARF  can  be  asymptomatic  or  present  with features  of azotemia  and  oliguria or anuria  and 
is diagnosed  when  biochemical  monitoring  of  hospitalized  patients  reveals  a  new  increase  
in blood  urea  and  serum  creatinine  concentrations.  ARF,  as  opposed  to  chronic  renal  
failure is  often  considered  to  be  reversible,  although  a return  to  baseline  serum  creatinine 
concentrations  post  injury  might  not  be  sufficiently  sensitive  to  detect  clinically  significant  
irreversible  damage  that  may  ultimately  contribute  to  chronic  kidney  disease(1). 
Its  incidence  in  the ICU  in  various  studies  is  shown  to  be around two thirds of number of 
admitted patients (which makes it comparable to the incidence of acute lung injury (ALI) and 
severe sepsis), while 4–5%  of  ICU  patients will  require some form of  renal  replacement  
therapy (RRT) (1). The incidence of ARF is increasing with a higher mortality in those who have 
more severe renal dysfunction. Even patients who have received dialysis have a mortality of 40-
50% (1).  
This study was done to evaluate the risk factors for ARF in a developing country as most 
published studies done so far have been done from developed countries. 
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LITERATURE REVIEW 
 A  survey  as  reported  in  a  recent  journal  quoted  more  than  35 definitions  in  literature  for  
ARF (1). ARF is   found commonly in ICUs (Intensive Care Units). Various  studies in  tertiary  
centers  quote  figures   ranging  from  1%  to 67% with mortality ranging from 20% to  40% (1).  
The  commonest  factors  for  the  same  being   sepsis  and  hypovolemia,  ARF is  found  to  be  
as  common  as  severe  sepsis  and  ALI (Acute  Lung  Injury).  ARF  is  found  to  induce 
incremental  involvement  of   the  coagulation  pathway,  the  lungs  and  the  central  nervous 
system.  
 
  DEFINTIONS OF ACUTE KIDNEY INJURY (AKI):   
         The term Acute Renal Failure was first introduced by Homer. W. Smith in his textbook (2). 
Unfortunately, a precise biochemical definition of this term does not exist.  The  occurrence of   
azotemia and  oliguria   is  actually  a  physical  response  to  renal  injury  and  may  actually  
express  a normally  functioning  kidney  trying  to  maintain  homeostasis.  Conversely,  a  
hypovolemic person  with  a  normal  urine  output,  actually  may  have  a  more  pathological  
kidney (3). Thus, the traditional term,  ARF,  does  not  define  a  specific  pathological  state  nor  
does  it  clearly  define a  clear   cut   criteria  beyond  which  one  can  confidently  say  that  a  
person  has  a malfunctioning   kidney.  In addition,  there  is  no  clear cut  identification  of  
acute  tubular  necrosis  or  pre  renal   failure.  
     Creatinine values and presence or absence of oliguria/ anuria was used in the assesment of 
renal function. The problems are associated with the use of the serum creatinine to quantitatively 
define ARF are as follows:  
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• Serum creatinine does not accurately reflect the GFR in a patient who is not in steady 
state. In the early stages of severe acute renal failure, the serum creatinine may be low 
even though the actual (not estimated) GFR is markedly reduced since there may not have 
been sufficient time for the creatinine to accumulate.  
• Creatinine is removed by dialysis. As a result, it is usually not possible to assess kidney  
function by measuring the serum creatinine once dialysis is initiated. One exception is   
when the serum creatinine continues to fall on days when hemodialysis is not performed   
indicating recovery of renal function. 
• Numerous epidemiologic studies and clinical trials have used different cut-off values for  
serum creatinine to quantitatively define ARF (4). 
 
        The lack of consensus in the quantitative definition of ARF has hindered clinical 
research since it confounds comparisons between studies. Some definitions employed in clinical  
studies have been extremely complex with graded increments in serum creatinine for different  
baseline serum creatinine values (3,4,5). As an example, in a classic study of the epidemiology of 
hospital-acquired acute renal failure, ARF was defined as an increase   in serum  creatinine  of  
0.5 mg/dL if the baseline serum creatinine was ≤1.9 mg/dL, an 1.0 mg/dL increase in serum  
creatinine if the baseline serum creatinine was 2.0 to 4.9 mg/dL, and a 1.5 mg/dL increase in  
serum creatinine if the baseline serum creatinine was ≥5.0 mg/dL (4).  
 
   The Acute Dialysis Quality Initiative (ADQI) was created by a group of expert intensivists and 
nephrologists to develop consensus and evidence based guidelines for the treatment and 
prevention of acute renal failure (5). Recognizing the need for a uniform definition for ARF, the 
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ADQI group proposed a consensus graded definition, called the RIFLE criteria (6). A 
modification of the RIFLE criteria was subsequently proposed by the Acute Kidney Injury 
Network, which included the ADQI group as well as representatives from other nephrology and 
intensive care societies.(5,6,7,8) 
In view of these deliberations, the term acute kidney injury (AKI) was proposed to represent the 
entire spectrum of acute renal failure.  
RIFLE CRITERIA:  The RIFLE criteria consists of three graded levels of injury (Risk, Injury, and 
Failure) based upon either the magnitude of elevation in serum creatinine or a decrease in urine 
output, and two outcome measures (Loss and End-stage renal disease). The RIFLE strata are as 
follows (5,6,9):  
• Risk — 1.5-fold increase in the serum creatinine or GFR decrease by 25 percent or urine  
output <0.5 mL/kg per hour for six hours 
• Injury — Twofold increase in the serum creatinine or GFR decrease by 50 percent or  
urine output <0.5 mL/kg per hour for 12 hours 
• Failure — Threefold increase in the serum creatinine or GFR decrease by 75 percent or  
urine output of <0.5 mL/kg per hour for 24 hours, or anuria for 12 hours 
• Loss — Complete loss of kidney function (e.g., need for renal replacement therapy) for  
more than four weeks 
• ESRD — Complete loss of kidney function (e.g., need for renal replacement therapy) for  
more than three months  
The RIFLE criteria has correlated with outcome (mortality) in a number of studies 
(10,11,12,13,14,15,16). 
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A systematic review of 13 studies demonstrated a stepwise increase in the relative risk of death 
inpatients who met the RIFLE criteria for various stages of AKI (16). Compared to patients who 
did not have AKI, patients in the RIFLE stages of "risk," "injury," and "failure" had increased 
relative mortality risks of 2.4 (CI 1.94-2.97), 4.15 (CI 3.14-5.48), and 6.37 (CI 5.14-7.9). 
Despite significant heterogeneity among studies, results from most individual reports were 
qualitatively similar. 
 
Limitations: There are several important shortcomings to the RIFLE criteria: 
• The "risk," "injury," and "failure" strata are defined by either changes in serum creatinine 
or urine output. The assignment of the corresponding changes in serum creatinine and 
changes in urine output to the same strata are NOT based on evidence. In the one 
assessment of the RIFLE classification that compared the serum creatinine and urine 
output criteria, the serum creatinine criteria was a strong predictor of ICU mortality, 
whereas the urine output criteria did not independently predict mortality (14). Thus, if the 
RIFLE classification is used to stratify risk, it is important that the criteria that result in the 
least favorable RIFLE strata be used (5). 
• As mentioned above, the change in serum creatinine during acute renal failure does not 
directly correlate with the actual change in glomerular filtration rate, which alters the  
assignment of that patient to a particular RIFLE level. As an example, in a patient with an 
abrupt decline in renal function in the setting of severe ARF, the serum creatinine might 
rise from 1.0 to 1.5 mg/dL (88.4 to 133 micromol/L) on day one, 2.5 mg/dL (221 mmol/L) 
on day two, and 3.5 mg/dL (309 micromol/L) on day three.                                                                    
According to the RIFLE criteria, the patient would progress from "risk" on day one to 
"injury" on day two and "failure" on day three, even though the actual GFR has been <10 
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mL/min over the entire period. This issue is intrinsic to any assessment of acute renal 
failure based upon the serum creatinine level. 
 
• It is impossible to calculate the change in serum creatinine in patients who present with 
ARF but without a baseline measurement of serum creatinine. The authors of the RIFLE 
criteria suggest back-calculating an estimated baseline serum creatinine concentration 
using the four-variable MDRD equation, assuming a baseline GFR of 75 mL/min per    
1.73  sq.m (5).  However, this approach has not been prospectively validated. 
AKIN CRITERIA:  Given these limitations, a modification of the RIFLE criteria has been 
proposed by the Acute Kidney Injury Network (AKIN). The AKIN proposed both diagnostic 
criteria for  ARF and a staging system that was based on the RIFLE criteria  (5,6,7,8) . In addition, 
the term acute kidney injury (AKI) was proposed to represent the entire spectrum of acute renal 
failure. 
 
Diagnostic criteria : The proposed diagnostic criteria for ARF are an abrupt (within 48 hours) 
absolute increase in the serum creatinine concentration of ≥0.3 mg/dL (26.4 micromol/L) from 
baseline, a percentage increase in the serum creatinine concentration of ≥50 percent, or oliguria of 
less than 0.5 mL/kg per hour for more than six hours . The latter two of these criteria are identical 
to the RIFLE "risk" criteria. The addition of an absolute change in serum creatinine of ≥0.3 mg/dL 
is based on epidemiologic data that have demonstrated an 80 percent increase in mortality risk 
associated with changes in serum creatinine concentration of as little as 0.3 to 0.5 mg/dL (17). 
Including a time constraint of 48 hours is based upon data that showed that poorer outcomes were 
associated with small changes in the creatinine when the rise in creatinine was observed within 24 
to 48 hours (18,19). 
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Two additional caveats were proposed by the AKIN group: 
• The diagnostic criteria should be applied only after volume status had been optimized. 
• Urinary tract obstruction needed to be excluded if oliguria was used as the sole diagnostic 
criterion. 
A flaw with the last caveat is that, according to the current definition, AKI would still be used to 
describe the patient with acute urinary tract obstruction and an acute increase in serum creatinine. 
It is not clear whether the AKIN modifications to RIFLE have substantively changed the 
classification of patients with AKI or improved its ability to predict hospital mortality (20). 
 
 Staging system: The classification or staging system for ARF is comprised of three stages of 
increasing severity, which correspond to risk (stage 1), injury (stage 2), and failure (stage 3) of the 
RIFLE criteria. Loss and ESRD are removed from the staging system and defined as outcomes. 
The clinical applicability of these staging systems is still uncertain. However, they will likely 
have some utility in standardizing the definitions for epidemiologic studies and for establishing 
inclusion criteria and endpoints for clinical trials. 
Ultimately it is hoped that these definitions will be replaced by more sensitive and specific 
biomarkers of renal injury.  The use of such biomarkers, analogous to troponin as a marker of 
myocardial injury, will permit development of a new paradigm for classifying acute kidney injury 
that is not solely dependent upon serum creatinine or other functional markers. 
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  CLINICAL UTILITY:  
 The RIFLE and AKIN criteria have helped to focus attention that decrements in renal function 
that result in small changes in serum creatinine concentration are associated with significant 
clinical consequences. However, the precise clinical utility of these criteria is uncertain. There is 
also an inherent confusion within these criteria as to whether prerenal and obstructive etiologies 
of ARF are subsumed in or are external to the definition of AKI (17). 
These criteria have greatest utility in epidemiologic studies and in defining consistent inclusion 
criteria and/or endpoints for clinical studies.  
 
EPIDEMIOLOGY OF ACUTE KIDNEY INJURY 
   AKI  occurs  in  approximately  67% of patients  admitted  to the  intensive care  unit (1) and  is  
commonly  associated  with  multiple  organ  dysfunction syndrome (MODS). A decade  ago, 
AKI   was  thought  to  be  a  benign  entity  that  could  be managed easily with  supportive  care 
and  dialysis. It  is  now  known  that  it  has  a significant  negative  impact  on  patient  morbidity  
and  mortality.  Although epidemiologic data clearly demonstrates  that  acute  kidney  injury  is  
independently associated  with increased  mortality, the  mechanisms  by  which  acute  kidney  
injury  causes death  remain unclear.  One  explanation  for the  increased  mortality  is  that  acute  
kidney injury  causes deleterious  systemic  effects  including  injury  to  other  organs (21). 
 
    In  India,  a  study  done  in  an  ICU  in  a  tertiary  care  hospital  showed  that  ARF ( acute 
renal failure)  was seen in  3.79%  of cases  in  the ICU  and  associated  with  poor  prognosis.  
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Presence  of  sepsis,  MOSF,  higher APACHE – II scores  and  ventilation  need  were  correlated  
with higher mortality  in  ARF  patients  in  the  intensive  care  unit (22). 
  ETIOLOGY OF AKI: 
    The etiology for AKI in ICUs has been extensively studied.  Some  of  the well known 
etiologies  of  the  same  are sepsis (23), diabetes (24), age (24), hypotension(25), hypovolemia 
(25), contrast  administration (26), nephrotoxic  drugs (27) , mechanical ventilation (28) and  
number of  days (28) for  which ventilation   was  done.   
   i) Age and Gender:  The elderly population is more prone to acute kidney injury (AKI) than 
younger populations. Older patients have less renal reserve because of reduced glomerular 
filtration rates due to anatomic/functional changes, and concomitant diseases such as 
hypertension, diabetes, atherosclerosis, heart failure, ischemic renal disease, and obstructive 
uropathy. The risk of AKI may also increase as a result of aggressive diagnostic and therapeutic 
procedures, which include medical agents, radiology, and surgical intervention. AKI in the elderly 
has a multifactorial pathophysiology due to different etiologies. Studies that have specifically 
compared prognosis of AKI in elderly versus young over the recent years suggest that age is a 
predictor of long-term outcome (29). Gender is also found to be a separate risk factor in patients 
with AKI. Studies have shown that men are more susceptible to develop AKI as compared to 
women (30,31). The exact cause has not been discovered, but benign prostatic hypertrophy (BPH) 
could be a factor (31).  
ii) Co morbidities:  As age increases there is an increase in associated co morbidities associated 
with these patients. Common among these are diabetes, hypertension, along with associated 
complications of these like CKD, IHD.  Studies done on patients in ICU with AKI have shown 
diabetics to be at a greater risk in developing AKI. The primary cause is a reduction in glomerular 
filtration rate (GFR) as diabetic nephropathy progresses, making patients susceptible to contrast 
induced AKI and hypovolemia.  Also co existing disorders like atherosclerosis could further 
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compromise renal function especially if there is any trauma or surgeries where there is 
manipulation of the aorta is involved (31). 
iii) Sepsis and MODS:  Fever or hypothermia, leukocytosis or leukopenia, tachypnea, and 
tachycardia are the cardinal signs of the systemic inflammatory response syndrome (SIRS). SIRS 
may have an infectious or a noninfectious etiology. If an infectious etiology is proven then the 
patient is said to have sepsis (32). This can result in the multiple organ dysfunction 
syndrome (MODS) which is defined as the dysfunction of more than one organ, requiring 
intervention to maintain homeostasis (32). The pathology of sepsis and MODS has been 
postulated to be due to: 
      a) Inflammatory response via inflammatory mediators leading to a cascade mechanism in the 
body causing a systemic inflammatory response syndrome.  The hallmark of septic shock is a 
decrease in peripheral vascular resistance that occurs despite increased levels of vasopressor 
catecholamines. Before this vasodilatory phase, many patients experience a period during which 
oxygen delivery to tissues is  compromised by myocardial depression, hypovolemia, and other 
factors. During this "hypodynamic" period, the blood lactate concentration is elevated, and central 
venous oxygen saturation is low. Fluid administration is usually followed by the hyperdynamic, 
vasodilatory phase during which cardiac output is normal (or even high) and oxygen consumption 
is independent of oxygen delivery. This is one of the postulated mechanisms via which the SIRS 
can lead to MODS i.e. the global hypovolemia leading to a tissue ischemia and hypoxia.  
  b) Another mechanism postulated is that of apoptosis. Apoptosis (programmed cell death) 
describes a set of regulated physiologic and morphologic changes leading to cellular death. This is 
the principal mechanism by which embryogenesis occurs or senescent /dysfunctional cells are 
normally eliminated. In addition, cell death via apoptosis is the dominant process leading to the 
termination of inflammation once infection has subsided. However, proinflammatory cytokines 
may delay apoptosis in activated macrophages and neutrophils. This effect may prolong or 
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augment the inflammatory response, thereby contributing to the development of multiple organ 
failure.  Derangements of apoptotic cell death are also believed to play a critical role in the tissue 
injury of sepsis. (33) Apoptosis is normally a physiologic mechanism to selectively limit cell 
populations with rapid proliferation (e.g., gut epithelium). When exposed to various inflammatory 
mediators, such as endotoxin, cytokines, and reactive oxygen species, parenchymal and 
endothelial cells respond by the induction of one of two programs of stress gene expression. 
When subsequently exposed to endotoxin, these cells undergo accelerated apoptosis. Gut 
epithelial apoptosis is an important factor in an animal model of Pseudomonas sepsis (34). 
iv) Tropical Infections: As per data from developing countries, tropical infections like scrub 
typhus, malaria, dengue, leptospirosis and enteric fever were associated with AKI. A study of all 
patients with tropical infections done in this centre showed an incidence of 41.1% of AKI; of 
which, 17.4%, 9.3% and 14.4% were in the Risk, Injury and Failure classes, respectively (35). 
The pathophysiology in leptospirosis leading to AKI is postulated to be due to a vasculitis that is 
commonly seen in the disease. In the kidney, leptospires migrate to the interstitium, renal tubules, 
and tubular lumen, causing interstitial nephritis and tubular necrosis. Hypovolemia due to 
dehydration or altered capillary permeability may also contribute to the development of renal 
failure (36). 
       Scrub typhus also known to cause AKI has a pathophysiology which leads to occlusive 
thrombosis and ischemic necrosis. However, these are not the fundamental pathologic basis for 
tissue and organ injury. Instead, increased vascular permeability, with resulting edema, 
hypovolemia, and ischemia, is responsible. Hypovolemia leads to prerenal azotemia and (in 17% 
of cases) hypotension. Renal failure, often reversible with rehydration, is caused by acute tubular 
necrosis in severe cases with shock (37). 
     AKI is common among adults with severe falciparum malaria. The pathogenesis of renal 
failure is unclear but may be related to erythrocyte sequestration interfering with renal 
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microcirculatory flow and metabolism. Clinically and pathologically, this syndrome manifests as 
acute tubular necrosis, although renal cortical necrosis never develops. Acute renal failure may 
occur simultaneously with other vital-organ dysfunction (in which case the mortality risk is high) 
or may progress as other disease manifestations resolve. In survivors, urine flow resumes in a 
median of 4 days, and serum creatinine levels return to normal in a mean of 17 days. Early 
dialysis or hemofiltration considerably enhances the likelihood of a patient's survival, particularly 
in acute hypercatabolic renal failure (38) . 
 
 v)  Intra abdominal hypertension (IAH): A new  concept  in  the  etiology  of  AKI in  the  ICU  
is  intra  abdominal  hypertension. In healthy individuals, a normal pressure (IAP) is less than 5 to 
7 mm Hg (39) according to the World Society of Abdominal Compartment Syndrome (ACS), and 
is usually diagnosed by measuring a patient’s intravesical pressure. An upper limit of 12 cms is 
generally accepted by the Society (39).Abdominal Perfusion Pressure = Mean Arterial Pressure 
(MAP) - Intra abdominal pressure (IAP)   
                                    Normal = 60 mm of Hg (39). 
A  sustained  IAP (intra abdominal pressure) of  > 20 mm  Hg  and  abdominal  perfusion pressure  
of  <60  mm  Hg  occurring  in association    with  a  new  and  attributable  organ  dysfunction  or  
failure  defines  the syndrome (40).  Primary   ACS  occurs  in  the  setting  of  injury  and  stems  
from  the  hemorrhage and  edema.   Secondary  ACS  occurs  in  both  surgical  and  medical  
patients  after  excessive resuscitation  due  to  fluid  therapy  leading  to  ascites  and  visceral  
edema.  This raised ACS can lead to   poor perfusion to the kidneys.  Therapeutic  interventions  
include  surgical decompression  and  other  local  therapies  like-  prosthetic  grafts,  skin  grafts  
or  flaps  for abdominal  wall  reconstruction.  However,  no  RCTs  have  been  done  to  show   
the  benefit of  one  therapy  over  the  other.  Thus, currently the gold standard of therapy for 
ACS is surgical decompression.  
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 vi) Hepatic dysfunction: An  increasing  number  of  patients  with  severe  liver  dysfunction  
are  admitted  to  the  ICU for  stabilization  and  organ-specific  support,  including  liver  
transplantation.  Global impairment  of  hepatic  performance  frequently  results  in  pathologic  
organ  interactions  that limit  the  potential  for  recovery.  One of the most notable of these 
interactions is the hepatorenal syndrome. This is a fatal  complication  of  end- stage  liver disease  
characterized  by  the  progressive  development  of  oliguria  and  low  urine  sodium excretion.  
The  syndrome  can  occur  in  the  setting  of  either  acute  or  chronic  liver disease, and  portal  
hypertension  is  important  in  the  pathogenesis.  The  patient  with the hepatorenal  syndrome  
also  has  a  number  of  systemic  circulatory  abnormalities induced  by liver  disease  and/or  
portal  hypertension,  but  the  exact  pathologic  role  of  these abnormalities  in  the development  
of  oliguria  is  uncertain. 
The following mechanisms are implicated in the development of hepatorenal syndrome (HRS): 
1. Splanchnic and peripheral vasodilatation with reduction in effective arterial volume causes 
activation of mechanisms leading to intense renal vasoconstriction and functional AKI. HRS is 
a diagnosis of exclusion and all other causes of AKI (especially prerenal azotemia) have to be 
considered and excluded (41).  
2. Circulatory dysfunction in cirrhotic patients may cause HRS. It contributes to the high 
incidence of renal failure in cirrhotic ICU patients. Fluid therapy may aggravate renal failure 
by increasing ascites and intra abdominal pressure. Information regarding this condition is still 
incomplete (41). It is reasonably well established that diminished systemic blood pressure is 
not the primary cause of renal insufficiency. Rather, intrarenal preglomerular vasoconstriction 
mediated by unknown stimuli is the major defect in the hepatorenal syndrome, manifested by 
relative ischemia. Current data point to abdominal renal sympathetic innervation as one of the 
more likely major causes of this vasoconstriction. 
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  After  exclusion  of  systemic  intravascular  volume depletion  and  other  causes  of  oliguria, 
dialysis  therapy  is  indicated  when  liver transplantation  or  recovery  of  liver  function  is 
anticipated;  terminal  supportive  care  is appropriate  when  these  outcomes  are  not  options.  
vii) Toxin and drug induced renal injury: Drugs with direct nephrotoxic effects may induce 
renal injury by several mechanisms. Most commonly, renally excreted drugs can exert direct toxic 
effects on renal tubules inducing direct cellular injury and death in acute tubular necrosis or 
induce inflammation in the renal interstitium in acute interstitial nephritis. These are generally 
caused by aminoglycosides. 
  Other types of nephrotoxic tubular injury include osmotic nephrosis induced by hypertonic 
solutions and tubular obstruction by drug precipitation (e.g. crystalline nephropathy caused by 
acyclovir and indinavir). Nephrotoxic acute tubular necrosis is generally a dose dependent 
phenomenon that predictably occurs in patients at high risk for renal injury (older patients,         
pre existing renal disease, multiple nephrotoxic agents used) and is characteristically 
noninflammatory in nature. In contrast, acute (allergic) nephritis is an idiosyncratic inflammatory  
response to drug exposure. Agents commonly implicated in these are penicillins; non steroidal 
anti inflammatory drugs (NSAIDs) and calcineurin inhibitors.  Drugs also may be indirectly 
nephrotoxic by modulating intra renal blood flow, thus rendering the kidneys vulnerable to 
ischemia and injury in the case of decreased renal blood flow such as those seen in angiotensin 
converting enzyme inhibitors (ACEIs), and NSAIDs.  Therapeutic agents have been associated 
with the development of glomerular disease or vasculitis; however, these are relatively rare 
complications of medical therapy commonly seen with penicillamine, gold and hydralazine (42). 
Radiocontrast has been attributed to an increase in the risk of  developing AKI. This is because in 
a patient who is already critically ill with severe  metabolic illness like sepsis with superimposed 
renal vasoconstriction, impaired vasodilatation, and medullary hypoxia, it can lead to an oxidative 
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stress and direct tubular  injury. Iodinated contrast being water soluble dwells in the urinary space 
of the glomerulus and renal tubules, causing direct toxicity to the renal tubular cells (24).  
 
RENAL PROTECTION STRATEGIES: 
 
     There  have  been  many  renal  protection  strategies  suggested  for  the  prevention  of  AKI.      
They are  
1) Hydration and volume loading. 
2) Maintaining renal perfusion pressure. 
3) Avoiding nephrotoxic medications like, amphotericin B, amino glycosides and   
prevention of radio contrast nephropathy. 
4) Pharmacologic protection.  
 
In  the  prevention  of  AKI  (at  least  in  some  causes),  the composition  of fluid  and  the  
optimal  rate  of  infusion  has  yet  to  be  defined.  Renal perfusion therapy  is  helpful  in 
reducing  the  AKI  incidence,  but  there  is  no  definite quantitative data  to  guide in  the  
therapy  for  the  same. However, it seems one of the best ways to prevent AKI. The  therapy  for  
maintaining  adequate  renal  perfusion  pressure  has to  be  individualized  for  each  patient.   
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Pharmacologic protection: 
    There have also been pharmacologic therapies suggested for AKI prevention. Not all have been 
deemed beneficial. These therapies are: 
a) Loop diuretics:  Meta analyses have shown no role for loop diuretics in the prevention of 
AKI (43).   
b) Dopamine agonists:  Dopamine  agonists  and dopamine  have  been  found  to  have  no  
benefit  in  reducing incidence  of  renal  injury (44).  However,  fenoldopam  a    selective  
dopamine-1-receptor  agonist, has been  shown  to  increase  renal  blood  flow  and  
glomerular  filtration  rate. A  recent  single centre  study  as  well  as  meta analysis  
showed that  fenoldopam  reduced  the  incidence  of renal injury  in  patients  in  ICU  
patients  or  those  undergoing major  surgery.  It  does  not seem  to  show  benefit  in  
contrast  induced  nephropathy (45). 
c) Natriuretic peptides: Natriuretic  peptides like aniritide  have  been  tried,  but  there  is  
still no conclusive  evidence  as  to  its use  in  AKI, and as of now is not recommended (46). 
d) Calcium channel antagonists:  A  meta  analyses  of RCTs  done  in  post  transplant 
patients  with  a  calcium  channel  blocker  called  isradipine was  found  to  show  no  
benefit, even  though  the  trials  included  were  heterogeneous  and used  varying  doses  of  
the drug (47).   
 e) N-Acetyl Cysteine:  N- acetyl cysteine (NAC) has antioxidant and vasodilatory properties. 
Although not well understood, a possible mechanism of benefit in contrast-induced 
nephropathy involves minimizing both vasoconstriction and oxygen free radical generation 
after radiocontrast agent administration. N-Acetyl cysteine  has  been  found  to  be  beneficial  
in  contrast  induced  nephropathy  as shown  in  meta  analyses  which  evaluated  its use  and  
found  that  it  prevented  the serum creatinine  from  rising.  But,  the  benefit  was found  to  
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be  found  only  in  prevention  of  serum creatinine  from  rising. There was no improvement 
in glomerular filtration rate. However,  current  recommendations  are  that  NAC  should  be  
used  prior  to  contrast  being  given(48).   
 
MANAGEMENT OF ESTABLISHED AKI: 
The  modality  of  treatment  in  AKI  used  is  either  continuous  renal  replacement  therapy 
(CRRT), intermittent hemodialysis(IHD)or slow  extended  daily  dialysis (SLEDD) Randomized  
controlled  trials  have  not  shown  a  benefit  of  CRRT  in  mortality over IHD  (49).   
Currently there  is  no  consensus  on  specific  dosing  for  dialysis  nor  the right  time  for  
dialysis  can be  made  in  patients.   The two principal outcomes that have been examined with 
CRRT and IHD are patient survival and recovery of renal function. A paucity of evidence exists 
that have examined these issues. However, current data suggest that survival and recovery of 
renal function are similar with both CRRT and IHD. The majority of studies comparing CRRT 
and IHD have been observational or retrospective case series (50,51,52,53,54).  There appears to 
be no survival benefit associated with CRRT after adjustment for severity of illness (55,56). 
   A paucity of data exists concerning the effect on mortality of peritoneal dialysis (PD) versus 
intermittent hemodialysis (IHD) or continuous renal replacement therapies other than PD in 
patients with acute renal failure. Most studies had shown that the mortality and incidence of renal 
recovery with acute PD was at least comparable to hemodialysis (57) To address this question, a 
prospective study was performed in Vietnam in which 70 patients with acute renal failure due to 
either malaria or sepsis (48 and 22 individuals, respectively) were randomly assigned to either 
peritoneal dialysis or continuous venovenous hemofiltration (CVVH) (58). A markedly increased 
risk of death was observed among the group administered PD (47 versus 15 percent, odds ratio 
5.1, 95 percent CI 1.6 to 16). In addition, the mortality rate for patients on CVVH was unusually 
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low. Possible reasons for the poorer survival in the PD group include lower overall creatinine 
clearance; use of acetate (not bicarbonate) in the PD dialysate, use of rigid PD catheters and other 
PD-specific factors that are not yet defined (59). 
    In  summary, there are  a  few  factors  that  can  be  modified  and  can   lead  to  a  reduction  
in  the number of  patients  with  AKI  and  also  in  associated  morbidity  and  mortality 
(18),(22).   
   Although there have been studies on renal failure in ICU patients, most of these are for Western 
centers. In India, patients are admitted to ICUs are younger, more likely to have a reversible cause 
such as infections (scrub typhus, leptospirosis, dengue fever, malaria) poisoning or envenomation 
and have lesser co morbidities. The resources available to treat AKI are also limited in most 
Indian settings. In view of this, the above study was done to stratify the data into the prevalence, 
risk factors and outcomes of AKI in our setting.  
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AIMS OF THE STUDY 
 
 To study Acute Kidney Injury (AKI) in a tertiary care Medical Intensive Care Unit in order to 
document the incidence, evaluate the risk factors for its development and study the outcomes in 
an Indian setting.  
 
 
 
 
 
 
 
 
 
 
 
  20
 
PATIENTS AND METHODS 
Inclusion Criteria 
All critically ill patients admitted in Medical Intensive Care Unit of the hospital.  
 
Exclusion criteria 
 Nil. 
 
Sample size     
Since  most  of the data  is  from  Western  ICUs   and  as  the patient  profile is different  from 
those in India, these numbers could not be used. The incidence of  dialyzed patients  in  the  
Medical ICU was used to calculate the sample size,  as that number  would give  an  estimate  of  
incidence with  definite  failure (F according  to  the RIFLE  criteria)  getting  admitted. An  
estimate  of the number  of  patients with  the  F  class of  AKI  were  identified  in  the patients 
admitted  in  ICU using  the dialysis database. The number was 33 out of a total of 132 patients 
admitted to ICU (25%). 
 Thus substituting p as 25% and q as 75% using the formula  
                                           √p x q ⁄   n 
      Where p was sample proportion (25), q was (100-p= 75) and n was 132. A standard error of 3.87 
was obtained. A  precision  of  8%  was  obtained  from  this value  with a  Z  of 1.96 being set        
and with  a confidence  interval  of  95%  to  estimate  an alpha error  of  0.05  using  the  formula  
                                      n =     z² x p x q / precision² 
where  z=1.96, P=25,  Q =75, and precision  was  8%,a sample size of 113 was obtained.  
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It was also intended to study 10 variables likely to be risk factors (age, gender, hypotension, 
primary diagnosis, co morbidities, APACHE II and MODS scoring systems, liver diseases, 
nephrotoxic drugs, radiocontrast exposure, duration of mechanical ventilation.) and using the rule 
of thumb of 10 patients for each risk factor, a figure of 100 was obtained which was about the 
same as obtained by the above formula.  
Data Collection 
a) Baseline Patient Information 
At the initial admission baseline profile demographic data profile (age, gender, and basic 
diagnosis including reason for admission including other co morbidities) were collected as per the 
enclosed proforma (Appendix 1). Their baseline clinical metabolic, hematological parameters 
were followed up during ICU stay as per protocol. Data collection also included complications, 
investigations and dialysis details. 
b)  Follow up assessment in ICU 
ICU readings were recorded every hour vitals viz: blood pressure, pulse rate, respiratory rate, 
sensorium, inotropic supports, ventilatory supports. The highest and lowest readings over the 
whole day were collected in the data sheet. Details of complications, daily arterial blood gas 
monitoring (ABG) parameters, metabolic and hematological parameters with information about 
antibiotics, and change in drug orders and use of radio contrast agents were also included.  
Relevant  information  about  the desired  factors  of  interest  was gathered which included:     a) 
co morbidities, b) duration of mechanical ventilation, c) hepatic dysfunction, d) APACHE II 
scoring and MODS scoring, e) hypotension, f) nephrotoxic drugs and g) exposure to 
radiocontrast.  A univariate  analysis  on   each  of  them  to  assess significance was done, 
followed  by a  multivariate  analysis  on   those  factors  found  to  be  significant  in  the initial  
univariate  analysis.  
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Statistical Methods 
Data entry was undertaken by a single investigator using Microsoft Excel. Data analysis was done 
using Statistical Package for Social Sciences Version 17. The degree of correlation between the 
onset of AKI with 10 factors under study and also the progression to death were studied and a 
univariate and multivariate analysis was performed. The method involved cross tabulation 
followed by logistic regression and Chi square analysis.  
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RESULTS 
1. Patient profile 
A total of 146 patients were included in the study from September 2009 to January 2010. The 
total number of patients admitted to the Medical ICU during the same period was 146 out of 
which 114 patients developed AKI which gave an overall incidence of AKI at 78.1%.  
Parameter Value 
Total number of patients 146 
Mean (SD) age in years 46.08 (±18.319) 
Age range in years 15-90  
Male: Female ratio 1.05:1 
 
a) Age distribution      The ages of patients ranged from 15 years to 90 years old. The mean        
(± SD) age was 46.08 years (± 18 years). 
  30 years 30-45 years 46-60 years 60 years Total 
NO AKI 13 (35.14%) 7 (17.5%) 3 (9.38%) 9 (24.32%) 32 
AKI 24 (64.86%) 33 (82.5%) 29 (90.62%) 28 (75.68%) 114 
Total 37 40 32 37 146 
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The  distribution  of patients  across various  age groups  was plotted and accordingly  they 
were  divided  into  4  groups and  the  incidence  of  AKI  in  each age  subgroup  was  analyzed  
to look  for  association  with  AKI. It  was  found  on  analysis  that  as   the  age advanced  the 
incidence  of  AKI  increased  and  it  was  found  to be  statistically  significant  with  a p value of  
0.04. 
 b) Gender:  There  were  a  total  of  146  patients  out  of which 71 were females and 75 were 
male. Out  of  these  49  women  and  65  males  developed  AKI. The  p  value for  the  same  was  
0.008  implying  that  this  difference  was  significant.                                                     
 Males Females Total 
No AKI 10 22 32 
AKI 65 49 114 
Total 75 71 146 
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2. Primary Diagnoses: 
 Primary Diagnoses Number (percentage) 
Non infectious  56 (38.4%) 
Non tropical bacterial infections 53 (36.3%) 
Tropical infections 32 (21.9%)
Liver  dysfunction 5 (3.2%)
 
1- Non infectious diseases, 2- Non tropical infectious diseases, 3- Tropical infections, 4- Liver diseases 
Breakdown of primary diagnoses in 
the study
1
38%
2
37%
3
22%
4
3%
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a) Non infectious causes:  This included   acute cardiac failure with pulmonary edema, non 
infectious causes of SIRS like (acute pancreatitis, pregnancy related illnesses etc), envenomations, 
suicidal hangings and cerebrovascular accidents 
 
 
Diagnostic category Number ( percentages) 
Cardiac pathology 26 (46.4%) 
Pregnancy related illnesses 5 (8.9%) 
Dyselectrolytemia 3 (5.3%) 
Cerebrovascular accidents (CVA) 8 (14.2%) 
Poisonings 5 (8.9%) 
Acute pancreatitis 5 (8.9%) 
Envenomations which included snakebites as 4 (7.3%) out of which 3 were snake bites.  
 
Breakdown of casues of non infectious etiology
1
47%
2
9%
3
5%
4
14%
5
9%
6
9%
7
7%
 
                                    
1- Cardiac pathology 2- Pregnancy related illnesses, 3- Dyselectrolytemia, 4- CVA,  5- Poisonings,                         
6- Acute pancreatitis, 7- Envenomations 
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b) Non tropical bacterial infections:    These included all infections caused by agents which were 
not confined to the tropics. The most common were sepsis and septic shock caused due to gram 
negative or gram positive bacteria. Viral encephlitides, fungal and parasitic infections and 
infections in post transplant patients were also included.   The analysis was based on the 
etiological agents identified i.e. if it was an agent not confined to the tropic then it was included 
in this category.  
Etiological agent / Syndrome Number (percentages %) 
Gram negative bacteria 14 (26.41%) 
Gram positive bacteria 12 (22.64%) 
Viruses 15 (28.30%) 
Unknown agent but with a  definite focus 12 (22.64%) 
 
Breakdown of non bacterial tropical 
infections
1
26%
2
23%
3
28%
4
23%
 
1- Gram negative bacteria, 2- Gram positive bacteria, 3-Viruses, 4- Unknown agent with a definite focus 
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c) Tropical  Infections:   These were studied separately as they were postulated to be one of the 
risk factors for development of AKI in the ICU. These included patients with malaria, dengue, 
scrub typhus, leptospirosis and tuberculosis.  
Tropical infections  Number (percentages %) 
Scrub typhus 22 (68.75%) 
Dengue fever 3(9.375%) 
Tuberculosis 2(6.25%) 
Malaria 4(12.5%) 
Leptospirosis 1(3.125%) 
 
Breakdown of tropical infections
1
70%
2
9%
3
6%
4
12%
5
3%
 
1- Scrub typhus, 2- Dengue fever, 3- Tuberculosis, 4- Malaria, 5- Leptospirosis 
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d) Liver diseases:  There was also a separate diagnostic category of patients admitted with liver 
disorders. This included those with acute liver diseases and those with acute on chronic liver 
diseases.  The duration for differentiating acute and chronic liver disease was taken as 6 
months. (42) This was included to study the correlation between liver diseases and AKI.   
Diagnosis Number (percentages %) 
Acute fatty liver of pregnancy 1 (20%) 
HELLP  syndrome ( hepatitis, ,elevated liver 
enzymes, low platelets) 
1 (20%) 
Budd Chiari syndrome  1 (20%) 
Decompensated chronic liver disease 2 (40%) 
 
Primary Diagnosis and AKI 
This table shows the breakdown of patients into those who had AKI and those who did not have 
AKI. 
 Non infectious Non Bact. 
Trop Infec. 
Tropical 
Infections 
Liver diseases Total 
No AKI 18 6 8 0 32 
AKI 38 47 24 5 114 
Total 56 53 32 5 146 
 
 
The  P  value  was  0.037  for  those  with  non tropical bacterial  infections,  0.56 for tropical 
infections and 0.78 for non infectious diseases. 
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3.  Co morbidities   of patients admitted in ICU: 
Co morbidities in patients were studied for   an association with AKI. This was the profile of all 
patients admitted to ICU                                   
Co morbidities Number ( Percentage) 
None 70   (47.9%) 
Diabetes Mellitus 47 (32.1%) 
Hypertension 32 (21.9%) 
Chronic Kidney Disease (CKD) 9 (6.2%) 
Chronic Liver Disease ( CLD) 6 (4.2%) 
Malignancies 15 (10.3%) 
Connective tissue disorders 1 (0.7%) 
The  break  up  according  to  AKI   in  each  category  was  as  follows:     
0
5
10
15
20
25
30
35
40
45
50
1 2 3 4 5 6 7 8 9
NO AKI 
AKI 
 
1- Nil, 2 – Diabetes, 3- Hypertension, 4- Ischemic heart disease, 5- Chronic kidney disease, 6- Chronic Liver 
disease, 7- Connective tissue disease, 8- Malignancies, 9- Miscellaneous 
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The  Chi  square  analysis  revealed   a  p value  of  0.38  implying  that  secondary  diagnosis 
was  not  significant  as  risk  factor  for  AKI,  however  on  evaluation  of each   individual 
disease, diabetes  was  found  to  be  a  risk  factor  for  AKI. 
 
4. APACHE II and MODS scores: 
 APACHE  II  score   among  patients  with  AKI  and  those  without  AKI was done   by 
calculating  mean  scores   in  both  groups   and  then  performing  tests  of  significance. The 
mean  score  in  patients  with AKI  was  and  those  without  AKI  was   as  mentioned  in the  
table  below.     
 
 Mean APACHE 2 score Std.deviation Std. error 
NO AKI 22.06 7.62 1.35 
AKI 27.93 9.07 0.85 
                                                   
The  p value  was  0.001  showing  a  significant  association  between  a  high  APACHE II score  
and  AKI.  
A  similar  method  was  used  for  assessing  relation  between MODS  scores  and  AKI,  
wherein  mean  scores  in  both AKI  and  non AKI  groups  were  calculated  and  then  a  paired   
t- test  was  done  to  see if this  difference  was  significant.  
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The  mean  MODS  score  in  AKI  and in those with no  AKI  was  as shown  in  the  table  
below:                                             
 Mean  MODS score Std. Deviation Std. Error 
NO AKI 7.88 2.84 0.5 
AKI 8.8 2.94 0.27 
The  p  value   was  .112  suggesting  no  statistically significant  relation  between  AKI  
development  and  MODS  score. 
5. Risk factors 
i) Hypotension:   
  Hypotension was defined as Mean arterial pressure (MAP) of less than 70 mm Hg  (10-11) 
where  
                   MAP = Diastolic pressure + 1/3 rd of pulse pressure  
Pulse pressure being the difference between the systolic and diastolic blood pressure [42]. 
The MAP was available on all ICU patients on monitors.  
  Hypotension  as  one  of  the  causes  of AKI  in  these  patients  was also  analysed 
 
. Hypotension absent Hypotension present Total 
No AKI 23 8 31 
AKI 47 50 97 
Total 70 58 128 
 
The   p  value  was  0.010  for  developing  AKI  suggestive  of   significant association  between 
AKI  and  hypotension. 
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ii) Duration of ventilation  
                                                              
 Number of patients Mean Std.  Std. Error 
NO AKI 32 6.9 0.47 0.78 
AKI 99 7.7 0.44 0.12 
                                 
 
 
There was   no correlation between duration of ventilation and AKI.  Means for  duration  in  the  
two  groups ( with  and  without  AKI)  were calculated  and  then analysed for significance. The 
P value was 0.275 showing no association between the two risk factors  
 
 
 iii) Liver dysfunction: 
In those with hepatic dysfunction, bilirubin levels,  transaminase levels  ( cut off of 40 IU/L)  and  
albumin  levels  ( level less than 3.5 mg/dl) were used    separately  to  assess if  each  of  this had  
any  bearing  on  the  risk  of   developing  AKI. The difference in these patients and those who 
were included with liver diseases in the primary diagnosis was as follows. These patients had liver 
involvement in the form of transaminitis and mild hyperbilirubinemia, but there was no evidence 
of hepatic failure as demonstrated by ammonia levels, prolonged prothrombin time and hepatic 
encephalopathy.  
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a) Bilirubin levels: 
 Patients were  classified  according  to    bilirubin  values  into those  who developed  AKI  
and those  who  did  not  and then  performed  tests  of  significance to  see if  there  was  a 
statistically  difference  in  the two  groups.                         
 Normal  Values Abnormal  
 Values
Data not available Total 
NO AKI 21 4 7 32 
AKI 65 37 12 114 
 
The P value for correlation of hyperbilirubinemia with AKI was 0.132 showing no correlation    
between the two. 
 
 
b) Enzyme levels: 
 A similar  method  to  the  one used  for  assessing  relationship  between  AKI  and  bilirubin 
was  used  for  assessing relationship  between the enzymes  and  AKI.  The enzymes studied 
were SGOT and SGPT.  The lab cutoffs for both of them were 40 IU/dl.  The enzymes were 
studied separately for their relationship to AKI.                    
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                                              SGOT and AKI evaluation 
     Normal Values Abnormal 
Values
Data not 
available
Total 
NO AKI 12 13 7 32 
AKI 32 70 12 114 
Total 44 83 19 146 
   
                                            SGPT and AKI evaluation 
 
                               Normal Values Abnormal Values  Data not available Total 
NO AKI 16 9 7 32 
AKI 55 44 12 114 
Total 71 53 19 146 
                           
 
The P values  for correlation between SGOT and SGPT with AKI respectively were 0.143 and 
0.503  suggesting  no  significant  association  between  AKI  and  transaminase  levels. 
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c) Serum Protein and serum albumin levels:As part of evaluation between AKI and liver 
abnormalities, a test of statistical significance  was  done  between  abnormal  albumin  levels  and  
those  who developed AKI.                            
 Normal Albumin Low Albumin Data not available Total 
NO  AKI 16 9 7 32 
AKI 38 62 12 114 
Total 54 71 19 146 
 
The correlation between AKI and hypoalbuminemia was found to be significant at 0.027 
suggesting a positive association. 
iv) Potentially Nephrotoxic drugs: 
Class of drugs Number ( percentages) 
None 45 (30.8%) 
Antibiotics 89 (61%) 
Cardiac drugs (ACEIs, digoxin) 8 (5.5%) 
Miscellaneous ( Phenytoin etc) 4 (2.7%) 
Distribution of nephrotoxic drugs used 
in ICU
1
31%
2
60%
3
6%
4
3%
 
1- None, 2- Antibiotics, 3- Cardiac drugs, 4- Miscellaneous 
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The association between AKI and potentially nephrotoxic drugs was as follows:                               
  No exposure to 
nephrotoxic drugs
Exposed to nephrotoxic 
drugs
Total 
NO AKI 10 22 32 
AKI 35 79 114 
Total 45 101 146 
 
The  drugs  most  commonly  used  in  the ICUs  were  antibiotics (beta  lactams, were most 
common),  cardiac  drugs  like  ACEIs, digoxin  and  diuretics,  and  others  like  acyclovir 
 phenytoin , heparin, ranitidine, omeprazole, and digoxin. 
 
       The P value  for association  between  AKI  and  nephrotoxic  drugs  was 0.556  implying  
no  statistical significance.  
 
 
 
v) Radio contrast exposure : 
  Exposure to  radiocontrast  was one  of  the  risk  factors  postulated  to  predispose to  AKI.    
This too was  studied  for  relation  to  AKI  in  the ICU.     
                                              
 Not     Exposed to Exposed  to  Total
NO AKI 25 7 32 
AKI 105 9 114 
Total 130 16 146 
                            
The P  value  in  this  was  0.03  implying   significant association   between developing  AKI  and   
exposure  to  radiocontrast. 
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6. Outcomes: The association between AKI and mortality was evaluated to assess the effect of 
development of AKI on mortality. 
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The  significance  of  this  was  0.043  showing  a  significant  association  between  AKI  and 
death. 
 
.  Alive Dead Total 
NO AKI 27 (77.1%) 8 (22.9%) 35 
AKI 66 (59.5%) 45 (40.5%) 111 
Total 93 53 146 
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A breakdown according to AKI class was done to assess the incidence of each class and the 
severity of AKI in this ICU. The results were as below. As patients were not followed out of ICU, 
there were no patients in the L category (Loss according to RIFLE criteria) who were identified.  
Class of AKI                      Incidence ( percentage)  
R ( Risk) 43 (37.7%) 
I (Injury ) 25 (21.92%) 
F (Failure) 35 (30.7%) 
L (Loss) 0 
E (End stage renal disease, ESRD) 11 (9.64%) 
 
Breakdown according to AKI Class 
1
37%
2
22%
3
31%
4
10%
 
1- R (Risk), 2- I (Injury), 3- F (Failure), 4- E (ESRD) 
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 A  subgroup  analysis  was  performed  to  look  for  correlation    between  class   of  AKI and 
survival  outcomes. 
AKI Class Alive Dead Total 
NO AKI 26 6 (23.07%) 32 
Risk 28 15 (34.8%) 43 
Injury 18 7 (25%) 25 
Failure 18 17 (48.6%) 35 
Loss 0 0 0 
ESRD 3 8 (72.3%) 11 
Total 93 53  146 
 
1, 23.07%
2, 34.08%
3, 25.00%
4, 49%
5, 72.30%
 
1-No AKI, 2- Risk, 3- Injury, 4- Failure, 5- End stage renal disease 
 
 
 
 
The p  value  noted  for  this  was  0.011  implying that  the class  of  AKI  had  a  bearing  on 
survival outcomes.  As per the table above, severity of class coincided with poor survival   
outcomes. 
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7.  Treatments  
 
 NO AKI Risk Injury Failure ESRD Total 
No HD 30 42 23 27 5 129 
Received HD 0 1 2 8 6 17 
Total 30 43 25 35 11 146 
Percentage 0 2.27% 8.00% 22.86% 54.55% 11.64% 
 
Breakdown of dialysed patients acc. to 
AKI class
1, 2.27%
2, 8.00%
3, 22.86%
4, 54.55%
 
1- Risk, 2- Injury, 3- Failure, 4- ESRD 
 
 
Patients  at  the  more  severe  end  of  the  spectrum  of  AKI received  HD  and a more  severe 
classification  of  AKI  was  associated  with  a  poorer  survival  outcome. The  number  of  
patients  in  the  L  category  could not  be  ascertained as  the  patients  were not  followed  out  of   
ICU. 
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MULTIVARIATE  ANALYSIS: 
 
 A muitvariate analysis was done at the end of the univariate analysis taking into consideration all 
the factors that were found to be significant and the results were as follows:        
Variable P Value 
Age 0.03 
Gender 0.02 
Diabetes 0.01 
Hypotension 0.01 
APACHE II score 0.02 
Non  tropical bacterial infection 0.02 
Radiocontrast 0.16 
Hypoalbuminemia 0.01 
 
  From  this  multivariate  analysis  we  concluded  that age, gender,  diabetes ,  hypotension,  a 
  high  baseline  APACHE  score,  non  tropical  bacterial  sepsis  and  hypoalbuminemia  were   
 predictors   of  developing  AKI  as  they  had  a statistically significant  association  with  AKI.     
The only   factor found  to  be  significant  in  the  univariate  but  not  significant  in  the 
multivariate  analysis  was  radiocontrast  nephropathy. 
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                             DISCUSSION    
                 
 
Acute  Kidney  Injury  has  been  widely  reported  in  ICUs  and has  been  associated  
with  multiple  etiologies and  risk  factors-  some of  which  are reversible  ( viz: hypotension ) 
and  others which  are irreversible  ( viz: liver  failure).  
This study was conducted as there was inadequate published data in a tropical ICU setting.  
One study carried  out  in  an ICU in  a tertiary care teaching hospital in India, found  a positive 
association between age,  sepsis, APACHE score  and  MODS  in the  development  of AKI (22). 
The  unique  case burden  seen  here is  unlike  those  in  Western  ICUs, where in ICU 
patients a) age is higher b) multiple co morbidities are present and patient profile may include 
high number of complicated post op cases (21,23,25,26) and mortality could be higher due to 
these factors. This is unlike an ICU population in India where the age is younger, co morbidities 
are less, and infections like malaria, scrub typhus and leptospirosis may form the bulk of patients. 
Thus, this study  was  done  to  see how the people  who developed  AKI  in  this  ICU  setting 
were different as  compared  to  the data available from Western ICUs.  It was also to observe the 
commonest AKI class in the ICU and its effect on mortality.  
           Hoste et al (13) found  that  in  the ICU setting  in Western  centers, there were  a  
higher percentage  of  patients  with  R  as   compared  to  I  and  F.  There were no patients   with 
L and E class of AKI.  The   results seen there were as follows: patients with maximum RIFLE 
class R, class I and class F had hospital mortality rates of 8.8%, 11.4% and 26.3%, respectively, 
compared with 5.5% for patients without acute kidney injury. As   mentioned  in  the  literature 
review  in  the beginning,  the  RIFLE classification   has  been  validated externally  and  has   
been  found  to  be  a  better predictor  of  AKI   than  serum  creatinine  alone.  
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A. Patient profile: 
            
    i) Overall Incidence: 
      The overall incidence was 78.1% which was more than that reported in other studies (1),(21), 
which could be because of the hospital being a tertiary care referral centre and the lag time for 
presentation for patients form various hospitals.  
    
 
  ii)Age:     
   This study found that an older age was a risk factor for developing AKI. This has been 
corroborated with other studies in both Indian and Western cohorts (18,22,29). The reason age is 
linked to AKI could be due to a reduced physiological reserve or increasing  co morbidities with 
increasing age   
 
iii)Gender: 
Gender was found to be a significant factor in development of AKI in this study. This is a 
finding that had been reported in a earlier studies while studies were being conducted to evaluate 
the nephrotoxicity of other factors (32,33). However, now the male gender is recognized as   a 
well known factor for developing AKI (34,60). 
  45
 
      B. Primary diagnosis: 
             As   part  of the analysis,   primary  diagnoses  ( the  main  reason   for admission 
into  ICU) were classified  into  non  infectious,  non tropical bacterial  infections,   tropical  
infections  and  primary  liver  disorders.  The  reason is  because  one  of  the common conditions 
causing renal  failure in this setting are  tropical  infections. It was   found that patients with   
bacterial infection and associated sepsis had higher   risk   of development of   AKI.  There was 
no higher risk for development of AKI   found    in patients   with tropical   infections in this 
study.   The role  of  sepsis    in  causing  AKI  though  not   fully  well  defined  has  been  well 
documented  and    this  was  confirmed  by  this  study (61). Envenomations esp. snake bites were 
not considered for analysis as there were only 3 patients in total and were too small a number to 
study for any associations.   Tropical infections have been well documented to have AKI (35). 
However, this study did not find it as association as a risk factor for developing AKI. The reason 
could be that in the case of scrub typhus, empirical Doxycyline is started early during the course 
of admission for any patient with high clinical suspicion (eschar, hepatitis, renal failure and 
thrombocytopenia). This disease is well known for its rapid response to antibiotics, which can 
explain why patients who came to ICU received early antibiotics and thus may not have 
developed AKI. There was only one case of leptospirosis during the course of the study and 
hence, this study is underpowered to study any association between the two. Dengue is a rapidly 
reversible cause of AKI if isotonic fluids are given to the patient once shock develops, as was the 
case in most patients coming to ICU. Malaria is a very common disease here and most patients 
who are admitted have already received artesunate or quinine prior to presentation, thus again 
leading to less patients presenting with severe renal dysfunction.  
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           A  univariate  analysis was done  on  the  various   factors  that  were  involved  in  
the liver  function  tests  done  in  this  hospital  viz: bilirubin  levels,  albumin levels and  
transaminases.   Hence, various  components  of  liver function  tests were used  to  ascertain  if 
any  of  them  had any association  with  AKI.  The  patients  who  came  with  acute  liver  
failure (hepatic disease)  were only  5 in  number  hence, this  study  was  underpowered to study  
any  relation  between the  two, though all patients who were admitted with this condition, were 
found to have AKI. The   rest  of  the  analysis was in  patients  with  mild liver dysfunction 
which was probably  a secondary  manifestation of  a  MOSF. In  these  only   a  low  albumin 
level ( below 3.5 mg/dl)  showed  a significant  co relation  with  AKI  in  the multivariate  
analysis. The  correlation between  AKI  and  hypoalbuminemia can  be explained  by a) 
albumin's  role as a  negative  phase  reactant, the sicker patients could have a lower albumin,  b) 
protein nutrition deficiency, c) proteolysis  occurring  in  critically  ill  patients  and the negative  
protein  balance.  Hypoalbuminemia has also been found to be an independent risk factor for 
AKI in both randomized controlled trials and meta analyses.(62,63).  
     
 C. Co morbidities: 
             
This study found that the presence of diabetes was a risk factor in development of AKI.  
Among  co  morbidities, chronic  liver disease  was   also included,  but  as there  were  only  6  
patients, it  is  underpowered  to detect  any  association  of  significance.  The finding that 
diabetics are at  a higher risk of developing AKI   fits  in  with  the   understanding  that  these 
patients  already  have  a  compromised  renal  function  and  diminished renal reserve  hence  the  
capacity  to withstand  another  insult is  limited. This predisposes these patients to higher chance 
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of developing AKI.  Indian and Western centers, have found diabetes to be a significant factor to 
be commonly seen in association with AKI. (10,11, 15,28). 
 
   D. Risk factors 
i) Hypotension: 
 This study found that like earlier studies, hypotension was a significant factor in         
development of AKI (16,18). Most  patients were having  hypotension  within the first  24  
hours of  admission  and  were  found  to  have  AKI  on  admission. 
 
iii)Nephrotoxic drugs:  
There  was  no association found between potentially nephrotoxic  drugs used in the ICU and  
AKI in  the  univariate  analysis  of  this  study,  though a few  other  studies done  elsewhere 
have   mentioned  these as a  common  cause for AKI (27).  The drugs commonly studied in 
these included NSAIDs, aminoglycosides, penicillins, amphotericin B and calcineurin 
inhibitors  However,  in  this  study ,the commonest  drugs  used  were  penicillins  [broad 
spectrum  like piperacillin  tazobactam]  and  angiotensin  converting  enzyme  receptors  
(ACEIs). Only two patients received Amphotericin B (26,64). NSAIDs and aminoglycosides 
were not used in the ICU. They are commonly identified in previous studies as risk factors 
for AKI (64). As part of a safe drug policy, aminoglycosides and NSAIDS are altogether 
avoided in the ICU. Thus the frequency of potentially nephrotoxic drugs used in ICU was not 
very high which can explain the low incidence of AKI noticed in our ICU. Also, the 
interstitial nephritis that is seen in penicillin use has been described as mainly idiosyncratic 
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which explains why even a high use of this class of drugs, was not a risk factor as per this 
study.  In addition, as the early use of antibiotics  would  have  taken  care  of  the underlying  
sepsis, the factors leading to  AKI  would actually have   improved  thus  actually  leading  to 
the  confounding  finding  of  low AKI in  spite  of such  high  beta lactams use.  As these  
drugs  comprised  more  than  95% of  drugs  used this could probably  be  the  reason  for  
low  incidence  of AKI in  this  group.  
iii) Radiocontrast exposure:     
There  was  significant  development  of  contrast  induced nephropathy  in  the  univariate  
analysis  but was  not found  to  be significant  on multivariate  analysis. The  reason  for  the  
low  rate  of  contrast  induced  nephropathy could that as all of  them  had  received adequate 
hydration  prior  to  the procedure which  would have reduced the incidence of  the same  in 
them. NAC was also used routinely for elective radiological procedures needing contrast.  
iv) Duration of mechanical ventilation: 
 Mechanical ventilation and its duration has been found to correlate with severity of AKI and 
its role in mortality according to studies (21,28). This study assessed the relation between 
these two factors and  this study found no association between development of AKI and 
duration of ventilation. The reason could be that earlier studies looked for an association 
between mortality, AKI and duration of mechanical ventilation. The patients who were on 
ventilator for more than 15 days were 5; (3 had AKI while 2 did not), which could explain 
the reason why there was no significance, as the study was probably underpowered. A           
t-test was done to compare the means of duration of ventilation between the two groups (AKI 
vs non AKI) and found no statistical significance between the two. It could be possible that 
the sicker patients with AKI may have actually had a shorter duration of ventilation as they 
were very morbid on admission and may have deteriorated rapidly in the ICU, causing early 
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mortality, leading to a confounding factor while trying to study association between these 
two factors.  
 
  E. Scoring systems: 
 
A significant finding was that of a higher APACHE II score in those with AKI. This  can  
be explained  on  the  basis  of  the  fact that  sicker patients are more likely to have renal failure. 
But there was   no correlation between a second scoring system MODS and AKI. This was 
probably because  APACHE II  gives  a more  comprehensive  analysis  of  the  patients condition  
including  more  factors included in the calculation  than  MODS.  As   seen  earlier, AKI  is a 
component of  multi   organ  dysfunction  and  can also be one  of  the risk factors   responsible  
for the  SIRS cascade  seen  in  patients  with  multi organ   dysfunction.  The  MODS   scoring  
uses  fewer  criteria  than  APACHE 2  scoring  and  may  not  always  be an  accurate  predictor 
for  developing  AKI  as  a more  complete  picture of the patient is  better picked up in a detailed 
scoring system like the APACHE II scoring system.   
 
F. Outcomes:  
 
A  sub  analysis  of  the  various  classes  of  AKI, their  incidence  and association  with  
mortality was  done. The  morbidity  and  mortality progressed  as  the  class  of  AKI progressed  
on  the  R  to  E scale along with the  necessity for  dialysis.  As  patients  were   not  followed  up  
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after  their  discharge  from  ICU, patients  could  not be  assessed  for  development  of L (Loss) 
class in RIFLE. 
 There  is definite correlation  between  class  of  AKI  and  mortality,  need  for  RRT  and  
an association  of  RRT  with  mortality.   
Another  important  finding  was  the  number  of patients  in  the  R and  I classifications 
who  would  have  been  classified  as  “normal”  under the  old  definition  of  renal failure, but  
were  detected to  have  AKI  under the  new  definition.  Though  the mortality  was  not  
significant  in  these  patients, and  none  received RRT, the fact that they had developed AKI 
which would have been missed by the earlier definition was noticed.  
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LIMITATIONS 
 
1. There were no patients who could be classified under the Loss (L) category in the 
RIFLE spectrum. 
 
2. There were limited numbers of patients in some of the subgroups to do a statistical 
analysis.  
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CONCLUSIONS 
 
In this cohort of patients admitted to the Medical ICU 
1. A higher risk of developing AKI is found with   advancing age,  male  gender,  a higher  
APACHE II score  at  admission ,  hypoalbuminemia, bacterial  infections, diabetes   and  
hypotension.  
 
2. The MODS score, liver diseases, tropical infections, the drugs used in the ICU, 
radiocontrast and other co morbidities were not associated with AKI. 
 
3. A high RIFLE score is associated with a higher need for dialysis and a poorer outcome.  
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APPENDIX I 
Data abstraction form – Thesis 
     PATIENT SERIAL NUMBER: 
Name:       Hospital Number:    
Age:       Sex:    State: 
Occupation:     Length: 
Diagnosis         Primary ( reason for admission to ICU) 
 
 
                          Secondary (co morbidities) DM 
                                                                         Hypertension  
                                                                         IHD 
                                                                         Autoimmune 
                                                                         Others 
 
Hospital    DOA                 DOD 
ICU           DOA                 DOD  
APACHE II                        MODS:                         
Outcome:   Alive / Expired/DAMA /Withdrawal 
 
Mechanical Ventilation Y/N                 Starting date                        Last date  
 
Non  Invasive ventilation Y/N              Starting date                         Last date 
 
Tracheostomy Y/N                                Date done 
 
 
Antibiotic treatment  
 
Radiocontrast agents with dosage 
 
 
Other nephrotoxic drugs 
DRUG Date of initiation of drug Date of stopping drug Dosage  
Beta lactams    
Vancomycin    
Amphotericin    
Aminoglycosides    
NSAIDs    
Diuretics    
Acyclovir    
Mannitol    
Phenytoin    
ACEIs    
Others    
Nosocomial infections: VAP / UTI / CRBI / Others 
 
 
 
Culture report:      
 
 
 
 
 
Cardiac arrest prior to arrest and duration if CPR if patient had an arrest 
Respiratory arrest prior to arrest 
 
 
Name Date of starting Dose Duration Indication 
     
     
     
     
     
     
     
     
 D1 2 3 4 5 6 7 8 9 10 
GCS            
Sedation           
Temp (max in Faren)           
HR >100/mt> 1 hr           
MAP< 70 >1hr           
Inotropes (Max) 
 
          
Inotropes (Min) 
 
          
Input           
Output           
Cumul balance           
Hb           
TC/DC           
Platelets            
PT/INR           
aPTT           
Na           
K           
Creat            
TB/DB           
Protein /albumin           
SGOT           
SGPT           
Alk. Phos           
Procal           
pH           
SpO2 ( Max)           
SpO2 ( Min)           
pCO2           
pO2           
HCO3-           
ABE           
Ventilation Mode           
FiO2 ( Max)           
FiO2 ( Min)           
PEEP (Max)           
PEEP (Min)           
RR ( Max)           
RR ( Min)           
TV (Max)           
TV (Min)           
PS           
CXR           
Adverse events if any           
       
CODES FOR MODE OF VENTILATION:   1-   NIV   2-SIMV  3-PCV  4-CPAP  
 
 CODES FOR INOTROPES 1- Adrenaline   2- Noradrenaline    3- Dopamine    4- Vasopressin  
 
 
 
 
 
 
 
 
 
 
SEROLOGY            Leptospirosis 
                                 HIV 
                                 HBsAg 
                                 Scrub typhus 
                                 HCV 
                                 HAV 
                                 HEV 
                                                               
DIALYSIS DETAILS                          
 
 
         
 D1 2 3 4 5 6 7 8 9 10 
Type           
Indication           
Duration           
           
           
           
 
 
 CODES FOR DIALYSIS: 1- SLEDD 
                                            2- Intermittent hemodialys 
                                    3-  Intermittent hemodiafiltration 
                                    4 - Intermittent ultrafiltration 
                                    5- Extended daily dialysis 
                                    6-Continuous therapies 
                                    7- Peritoneal dialysis 
                                    8- Continuous renal replacement therapies 
 
                                              
 
 
 
 
CODES FOR INDICATIONS   1-  Refractory Metabolic acidosis  
                                                   2-  Refractory hyperkalemia 
                                                   3-  Pulmonary edema/ ARDS  
                                                   4-  Uremic sgns and symptoms 
                                            
                                             Appendix II             DATA MASTER SHEET 
                                        
 
S.No Pt In. No Age Gender Diag. 
Co 
morbid 
Scoring Systems AKI AKI MV GCS Outcome 
APACHE 2  MODS      
1 GE 535114d 35 0 2 0 23 5 1 2 1 10T 0 
2 VS 504014d 24 1 0 0 19 5 1 1 0 15 0 
3 UV 821178c 42 0 2 0 37 9 1 3 1 4T 1 
4 VA 632428d 20 0 0 0 37 10 1 1 1 2T 3 
5 SA 328935d 49 0 0 0 35 10 1 1 1 2T 1 
6 CR 461512d 50 1 0 1 25 2 1 5 0 15 3 
7 VE 597204d 35 1 1 0 34 12 1 1 1 2T 0 
8 PE 603076d 81 1 1 1 36 6 1 1 1 2T 0 
9 DB 535359d 61 1 1 1 24 4 1 1 1 15 0 
10 JL 632306d 39 0 0 0 15 6 0 0 0 15 0 
11 SM 828284c 69 1 2 5 35 8 0 0 0 15 0 
12 MP 589613d 61 0 2 7 26 8 0 0 1 2T 1 
13 LV 605745d 21 0 0 0 20 8 0 0 0 12 0 
14 VA 507671c 84 0 1 0 26 11 0 0 0 8 0 
15 JL 156098a 69 0 0 9 24 9 0 0 1 2T 1 
16 VV 595896d 56 1 0 2 14 6 1 1 1 2T 1 
17 SA 244862d 62 0 0 3 21 6 0 0 1 2T 0 
18 PM 613358d 45 1 0 0 14 10 0 0 1 2T 0 
19 MA 554350d 76 0 0 0 26 9 1 3 1 2T 0 
20 KS 530171d 45 1 1 2 34 8 1 3 1 2T 1 
21 V 603214d 26 0 1 0 31 12 0 0 1 2T 4 
22 JS 587671c 84 0 2 2 25 8 0 0 0 14 0 
23 SA 638327d 16 0 0 5 10 8 1 1 0 15 0 
24 AB 603567d 68 0 1 0 28 8 0 0 0 10 0 
25 LA 036472c 74 0 0 1 36 9 1 1 1 2T 1 
26 PA 433985d 33 1 2 0 29 14 1 1 1 2T 1 
27 LA 582380d 65 0 0 1 32 5 1 1 1 2T 0 
28 HA 856487c 58 1 0 7 25 6 1 1 0 15 0 
29 VA 559260d 30 0 1 0 26 7 1 1 1 12 0 
 
Codes:::: DIAGNOSIS: 0- Non infectious, 1- Non tropical bacterial infections, 2- Tropical infections, 3-Liver diseases  
COMORBIDITIES: 0- None, 1- Diabetes, 2- Hypertension, 3- Ischemic heart disease, 5- Chronic Kidney Disease, 6- Chronic Liver disease, 7- Connective tissue disorder, 8- Malignancies,  
 
 
 
 
S.No 
In.  No Age Gender Diag. Co 
morbid 
Scoring systems AKI AKI Class M
V 
GCS Outcome 
APACHE MODS 
30 SP 512637d 25 0 1 7 39 11 0 0 1 5T 1 
31 RA 838895b 68 1 1 7 35 8 1 3 1 2T 0 
32 PL 587629d 44 0 1 0 13 6 1 3 0 15 0 
33 BS 601817d 61 1 2 1 33 11 0 0 1 2T 0 
34 SA 559269d 30 0 0 0 26 12 0 0 1 6T 0 
35 MO 850478c 58 1 1 7 25 6 1 1 0 15 0 
36 DN 472291d 44 1 1 2 13 8 0 0 0 10T 0 
37 PA 472009d 16 1 1 0 7 2 0 0 1 10T 0 
38 JA 540188d 61 1 0 9 33 9 0 0 1 2T 0 
39 MA 535461d 35 0 0 0 17 11 0 0 1 15 0 
40 VR 544553d 17 1 0 0 24 9 0 0 1 2T 0 
41 GA 543674d 19 0 2 0 33 10 1 1 1 2T 3 
42 SA 559231d 18 0 3 0 10 2 0 2 0 15 1 
43 RA 518129d 35 1 2 0 16 9 0 0 0 15 0 
44 DL 518041d 21 0 2 0 24 10 0 0 0 15 0 
45 JR 244872c 62 0 2 3 21 6 0 0 1 2T 0 
46 KK 474154d 36 0 0 0 19 4 0 0 0 14 0 
47 GE 302816d 18 0 0 0 32 7 0 0 1 2T 1 
48 BR 472280d 24 1 0 0 17 10 0 0 1 2T 3 
49 RA 569269d 30 0 0 0 19 6 0 0 1 6T 0 
50 CS 561641d 53 0 0 0 20 8 0 0 0 15 0 
51 SA 549328d 25 0 0 0 11 3 0 0 0 15 0 
52 SR 108718c 41 1 2 0 22 9 0 0 0 15 0 
53 AM 563777d 28 0 2 0 16 5 1 2 1 15 0 
54 GE 600067d 39 0 2 0 18 4 0 0 1 2T 0 
56 GE 563474d 19 0 1 0 28 8 1 0 1 2T 3 
57 SA 608550d 70 0 3 8 41 13 1 1 1 2T 0 
58 LB 613160d 75 0 1 1 48 12 1 5 1 2T 1 
59 CA 613347d 75 0 1 1 27 8 1 1 0 15 0 
60 PA 644333d 32 1 1 0 30 9 1 3 1 7 0 
 
Codes:::: DIAGNOSIS: 0- Non infectious, 1- Non tropical bacterial infections, 2- Tropical infections, 3-Liver diseases  
COMORBIDITIES: 0- None, 1- Diabetes, 2- Hypertension, 3- Ischemic heart disease, 5- Chronic Kidney Disease, 6- Chronic Liver disease, 7- Connective tissue disorder, 8- Malignancies, 
9- Miscellaneous   
 
S.No Pt 
In. No Age Gender Diag. 
Co 
morbid 
Scoring 
Systems AKI 
AKI 
Class MV 
G
C
S 
Outc
ome  
61 GS 630498d 53 1 0 1 21 10 1 3 1 15 0 
62 MA 554350d 76 0 0 0 26 9 1 3 1 2T 0 
63 BA 591006d 50 1 2 0 43 15 1 3 1 2T 1 
64 MR 563407d 53 1 1 1 32 5 1 1 1 2T 0 
65 JR 608199d 65 0 0 1 43 13 1 1 1 2T 1 
66 DA 638554d 39 1 0 1 33 11 1 3 1 4T 1 
67 NJ 497807d 45 1 1 1 40 13 1 1 1 3 1 
68 RS 535388d 54 1 1 7 21 16 1 2 1 2T 1 
69 VL 599401d 19 0 1 0 17 8 1 1 1 15 0 
70 SA 672485a 80 0 2 1 36 8 1 2 0 11 1 
71 MO 608599d 55 1 1 2 34 13 1 2 1 3 0 
72 BV 699293b 73 1 1 2 36 10 1 2 0 2T 1 
73 SH 033047d 63 1 1 2 39 7 1 1 0 3 0 
74 MH 330130b 90 1 0 0 34 6 1 2 0 3 0 
75 RB 190357d 60 1 0 1 27 5 1 2 0 15 0 
76 PA 330130c 75 0 1 1 48 12 1 5 1 2T 1 
77 RA 644152d 15 1 1 0 22 10 1 2 1 15 0 
78 KA 645722d 68 0 2 1 27 6 1 3 0 15 0 
79 RA 5938580d 40 0 0 7 17 8 1 5 1 15 1 
80 AB 392672d 55 0 1 1 26 6 1 3 1 3 1 
81 SU 596620d 57 1 1 1 40 7 1 3 0 3 0 
82 JE 604149d 45 1 1 1 40 13 1 3 0 3 1 
83 KP 603059d 35 0 3 0 37 11 1 1 0 3 1 
84 KM 305073c 61 0 0 4 28 7 1 5 1 15 0 
85 NN 597298d 33 0 0 0 44 13 1 3 1 2T 0 
86 ZO 405991a 47 0 0 7 38 9 1 2 0 2T 1 
87 FB 535355d 65 1 0 1 36 8 1 3 0 15 1 
88 SB 593580d 40 1 0 0 28 14 1 3 0 15 1 
89 MR 569598d 45 1 0 5 17 13 1 3 1 3 1 
90 JO 159208 70 1 3 2 22 5 1 5 1 15 0 
91 CN 763636d 63 0 0 2 30 4 1 2 0 15 0 
92 JA 620556d 21 1 2 0 33 13 1 2 1 2T 0 
93 MA 554350d 76 0 0 0 26 9 1 3 1 2T 0 
94 VE 213832c 74 1 1 3 13 6 1 1 3 15 0 
 
Codes:::: DIAGNOSIS: 0- Non infectious, 1- Non tropical bacterial infections, 2- Tropical infections, 3-Liver diseases  
COMORBIDITIES: 0- None, 1- Diabetes, 2- Hypertension, 3- Ischemic heart disease, 5- Chronic Kidney Disease, 6- Chronic Liver disease, 7- Connective tissue disorder, 8-malignancies 
 
 
 
S.No Pt 
In. No Age Gender Diag. 
Co 
morbid 
Scoring Systems AKI AKI Class MV 
GC
S Outcome 
APACHE MODS      
95 ML 630103d 40 1 0 0 13 6 1 3 0 15 0 
96 SR 472037d 42 1 2 0 16 10 1 3 1 15 0 
97 VA 556816d 25 0 2 0 13 5 1 1 1 15 0 
98 SI 630008d 35 0 2 0 13 7 1 2 0 15 0 
99 ML 630131d 38 0 2 0 26 9 1 3 0 10T 0 
100 JS 577164d 36 1 2 0 21 7 1 3 0 15 1 
101 LN 548449d 51 0 1 0 40 13 1 1 0 2T 1 
102 EP 535147d 53 1 2 1 46 11 1 3 0 2T 1 
103 NE 325977d 25 1 0 0 24 8 1 1 0 6T 0 
104 RE 528848d 57 1 0 7 25 10 1 3 0 15 0 
105 JK 469607d 28 1 0 0 28 13 1 2 1 4T 0 
106 KC 476626d 42 0 0 8 11 6 1 2 0 15 0 
107 SR 624619d 49 1 1 8 18 5 1 2 0 15 0 
108 CH 654402d 51 0 0 1 41 7 1 3 1 2T 0 
109 RO 469554d 23 1 1 1 35 11 1 5 1 6T 1 
110 SS 475844d 30 1 0 0 20 8 1 2 1 15 1 
111 KS 554210d 34 1 0 0 29 11 1 1 1 5T 2 
112 SM 472278d 40 1 0 1 24 7 1 3 1 10T 0 
113 RA 541556d 56 1 1 7 26 14 1 3 0 15 1 
114 SS 401589d 38 1 1 7 14 8 1 1 1 15 4 
115 PA 578208d 55 0 1 0 18 10 1 3 0 15 0 
116 SA 465858d 62 1 2 9 19 6 1 3 0 15 3 
117 RA 440932b 64 0 0 1 20 6 1 3 0 15 1 
118 GA 530448d 18 1 1 0 29 7 1 3 1 2T 1 
119 PR 620033d 51 1 0 1 39 13 1 3 1 3 0 
120 KS 603076d 81 1 1 9 23 9 1 1 1 2T 0 
121 GA 597182d 25 0 1 7 33 9 1 2 1 2T 0 
122 SM 607810d 39 1 1 8 28 11 1 1 0 15 3 
123 AM 461695d 30 1 1 0 11 7 1 3 1 4T 1 
124 MA 554350d 76 0 0 0 26 9 1 3 1 2T 0 
125 PM 306747c 73 0 2 0 37 8 1 1 1 2T 0 
 
 
Codes:::: DIAGNOSIS: 0- Non infectious, 1- Non tropical bacterial infections, 2- Tropical infections, 3-Liver diseases  
COMORBIDITIES: 0- None, 1- Diabetes, 2- Hypertension, 3- Ischemic heart disease, 5- Chronic Kidney Disease, 6- Chronic Liver disease, 7- Connective tissue disorder, 8-malignancies 
                                            
                                           
 
 
 
 
 
 
 
 
 
S.No Pt 
In. No Age Gender Diag. 
Co 
morbid 
Scoring 
Systems AKI 
AKI 
Class MV 
G
C
S 
Outco
me  
126 RA 470378d 60 1 0 0 27 6 1 1 1 15 0 
127 SA 550527C  25 0 0 0 12 4 0 0 0 15 0 
128 PA 563919d 45 1 0 0 32 11 1 1 1 2T 0 
129 SU 603246d 39 0 2 0 33 8 1 2 1 2T 1 
130 BH 306747c 73 0 0 3 27 6 1 1 1 2T 0 
131 KD 434410d 44 1 0 5 37 12 1 3 1 2T 2 
132 VL 608377d 38 0 1 7 27 7 1 2 1 2T 0 
133 MO 608599d 55 1 1 0 34 13 1 2 1 3 0 
134 MA 605729d 24 0 2 1 26 9 1 1 1 2T 1 
135 RK 597182d 25 0 2 7 33 9 1 2 1 2T 0 
136 LA 577052d 40 0 1 0 29 6 1 1 0 5T 0 
137 VK 597412d 54 1 0 0 18 9 1 1 1 15 2 
138 SB 540268d 20 0 2 0 26 13 1 1 1 15 0 
139 KO 653370d 28 0 0 0 22 9 0 0 1 2T 0 
140 PA 549323d 25 0 0 0 11 3 1 1 0 15 0 
141 DN 530134d 46 1 0 1 26 8 1 2 1 4T 0 
142 JE 644333d 32 0 0 1 34 14 1 5 1 2t 1 
143 MS 236835b 52 1 0 8 29 11 1 3 1 7 1 
144 TA 476644d 54 0 1 8 29 11 0 0 1 8 0 
145 SK 593994d 24 1 1 1 18 8 1 3 0 3T 1 
146 BS 5277556d 49 1 0 6 29 11 0 0 1 3 1 
 
Codes:::: DIAGNOSIS: 0- Non infectious, 1- Non tropical bacterial infections, 2- Tropical infections, 3-Liver diseases  
COMORBIDITIES: 0- None, 1- Diabetes, 2- Hypertension, 3- Ischemic heart disease, 5- Chronic Kidney Disease, 6- Chronic Liver disease, 7- Connective tissue disorder, 8-malignancies 
 
 
 
 
 
 
 
Appendix III                                 
                                          APACHE II SCORE  
 
Total Acute Physiology Score (APS) Sum of the individual 12 points = A 
Total APACHE 2 score = Sum of A ( APS) +B ( age)+ C (chronic health points) 
C= Chronic health points  
• Elective post op      +2 pts 
• Non operative or emergency post op +5 pts  
• If any of the below is yes give +5 pts:     1) cirrhosis with portal hypertension or hepatic encephalopathy 2) class IV angina at rest 3) chronic 
hypoxemia, hypercapnia or polycythemia 4) chronic peritoneal or hemodilaysis 5) Immunocompromised host  
 
 
 
HIGH ABNORMAL LOW ABNORMAL 
 +4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature (rectal) >41 30-40.9  38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 <29.9 
MAP= (2xdaistolic+ systolic)/3 >160 130-159 110-129  70-109  50-69 40-54 <49 
Heart rate >180 140-179 110-139  70-109  55-69 40-54 <39 
Respiratory rate  >50 35-49  25-34 12-24 10-11 6-9  <5 
Oxygenation 
a) FiO2>0.5 then A-aDO2 
b) FiO2<0.5 then PaO2 
>500 350-499 200-349  <200 
 
PO2 >70 
PO2 61-
70 
 pO2 55-60 pO2 
<55 
Arterial pH/serum bicarb if no ABG avail. >7.7/>52 7.6-7.69/ 
41-51.9 
 7.5-7.59/  
32-40.9 
7.33-7.49/ 
22.31.9 
 7.25-7.32/ 
18-21.9 
7.15-7.24/ 
15-17.9 
<7.15
/ 
<15 
Na >180 160-179 155-159 150-154 130-149  120-129 111-119 <110 
K >7 6-6.9  5.5-5.9 3.5-5.4 3-3.4 2.5-2.9  <2.5 
Creat >3.5 2-3.4 1.5-1.9  0.6-1.4  <0.6   
Hematocrit >60  50-59.9 46-49.9 30-45.9  20-29.9  <20 
WBC count >40  20-39.9 15-19.9 3-14.9  1-2.9  <1 
GCS 
(15-actual GCS)= The Score  
         
 
 
Age points (years): <44=0, 45-54= 2, 55-64= 3, 65 to 74= 4, > 75 = 5.  
 
 
 
 
 
 
 
 
 
 
    MODS scoring  
 
      
 0 1 2 3 4 
Respiratory (P/F ratio) >300 226-300 151-225 76-150 <75 
Hematological 
(platelets x 1000) 
>120 81-120 51-80 21-50 <20 
Hepatic 
(bili mg/dl) 
<1.2 1.2-3.5 3.5-7 7-14 >14 
CVS 
(HRxCVP/MAP) 
<10 10.1-15 15.1-20 20.1-30 >30 
GCS 15 13-14 10-12 7-9 <6 
Renal  (mg/dl) <1.1 1.2-2.3 2.3-4 4-5.7 >5.7 
      
 
